1. What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

3. Sequencing Therapy in mCRC Introduction

4. Case Study

5. Role of Maintenance Therapy

6. Second-Line Therapy in mCRC

7. Second-Line mCRC Anti-EGFR Therapy

8. Role of Tumor Sidedness

9. CALGB/SWOG 80405: Effect of Primary Tumor Location on OS and PFS

10. Case Study (cont)

11. RECOURSE Phase 3 Trial TAS-102 for Refractory mCRC

12. CORRECT Trial Regorafenib Monotherapy for mCRC

13. Regorafenib Dosing

14. MCRC BRAF V600E Mutant Right-Sided Tumors

15. SWOG 1406: Vemurafenib in mCRC BRAF Inhibitor

16. BRAF V600E Mutant mCRC Ongoing Clinical Trials

17. Non-V600E Mutated Tumors

18. Microsatellite Instability Status

19. Ongoing Clinical Trials in dMMR or MSI-High CRC

20. Phase 1 Cobimetinib + Atezolizumab in Unresectable mCRC

21. Concluding Remarks

22. Abbreviations

23. Abbreviations (cont)